Selection of Human-origin Lactobacillus strains as Probiotics with Capability in Synthesizing Conjugated Linoleic Acid and Alleviating Hyperglycemia in Rats (Rattus norvegicus) in vivo

• Main Authors: Widodo, Widodo, Harsita, Pradiptya Ayu, Anindita, Nosa Septiana, Wahyuningsih, Tutik Dwi, Nurrochmad, Arief
• Format: Conference or Workshop Item PeerReviewed
• Language: English
• Published: 2015
• Subjects: Food technology
• Online Access: https://repository.ugm.ac.id/135791/1/Gabung%20ISTAP.pdf; https://repository.ugm.ac.id/135791/
• Institution: Universitas Gadjah Mada

The objective of this study was to select Lactobacillus strains as potential probiotics with the capability to synthesize bioactive compounds Conjugated Linoleic Acid (CLA) and their ability to alleviate hyperglycemia in rats (Rattus norvegicus) in vivo. Five strains of Lactic Acid Bacteria consists of Lactobacillus casei strain AP and AG, and Pediococcus acidilactici strains AA, BE and BK were previously isolated and identified from faeces of infants who consumed breast milk as the only source of diet. In vitro evaluation those five strains showed their potential as probiotic based on their capability to grow on media with pH 2.0 and 1.5% concentration of bile salts, the ability to attach on gastric mucin in vitro, and their ability to inhibit the growth of pathogen. Evaluation on the ability to use prebiotic inulin as carbon source showed that Lactobacillus casei (strain AP and AG) and Pediococcus acidilactici strain BE had the ability to degrade inulin as a prebiotic. Evaluation of probiotic on their capability to synthesize Conjugated Linoleic Acid (CLA) from free linoleic acid showed that Lactobacillus casei strain AP was able to convert more than 60% of free linoleic acid to CLA in the media. Further in vivo studies using rats (Rattus norvegicus) showed that Lactobacillus casei strain AP had the ability to alleviate hyperglycemia. The ability of Lactobacillus casei strain AP in reducing hyperglycemia was comparable with that of metformin (anti-hyperglycemia drug) provided orally at level 45 mg/kg of body weight.